Check · Frontier · Young blood and plasma exchange In review

Do young blood, plasma, or plasma exchange reverse aging in humans?

Claim attributed to Ambrosia (founder Jesse Karmazin), which sold young-plasma infusions for about $8,000, plus cash-pay clinics offering therapeutic plasma exchange for "rejuvenation." , Ambrosia charged roughly $8,000 per young-plasma infusion and ran a paid study with no placebo arm; it halted patient treatments within hours of the FDA's February 2019 safety statement. Clinics now market plasma exchange for anti-aging by extrapolating from mouse parabiosis and disease-specific trials.

Verdict Unsupported

Evidence grade C Low certainty

In mice, surgically sharing a young circulation does rejuvenate aged tissue; in humans, no controlled trial shows that infusing young plasma reverses aging, and the FDA warned the commercial product has no proven benefit. The "reverses aging in humans" framing is unsupported; the dilution and plasma-exchange research behind it is merely unproven.

It rejuvenates a surgically conjoined mouse; for a human writing a $8,000 check, the proof simply is not there, and the regulator says so.

The theory

What it’s supposed to target

Circulating pro-aging factors
GDF11 (contested)
Plasma dilution
Heterochronic parabiosis

Parabiosis, joining an old and a young mouse into one bloodstream, rejuvenated some aged tissues, which spawned two rival theories. The romantic one: young blood carries rejuvenating factors (the much-hyped, much-contested candidate was GDF11) that an old body has lost. The more sober, newer one (Conboy lab): the benefit comes mostly from diluting the pro-aging factors that accumulate in old plasma, so simply removing and replacing old plasma, no youth required, may do most of the work.

Both ideas rest on real mouse biology, and therapeutic plasma exchange is a legitimate, approved procedure for specific diseases. The over-reach is selling young-plasma infusions as human anti-aging: the GDF11 story is disputed, no controlled trial shows rejuvenation in healthy people, and the FDA warned in 2019 that such infusions have no proven benefit and real risks. Tellingly, if anything works here, the dilution mechanism implies young donors are beside the point.

Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.

The claim

What would have to be true

The mouse parabiosis benefit would have to transfer to humans through infusion rather than shared surgical circulation (this link does NOT hold; the human analog is an untested extrapolation).

A youthful blood factor, or dilution of aged factors, would have to act the same way when delivered as a transfusable product (partially holds in mice via dilution; the single-factor GDF11 story does NOT hold).

A rigorous, placebo-controlled human trial would have to show rejuvenation or slowed aging in healthy people (this link does NOT hold; no such trial exists, and the FDA found no proven benefit).

The evidence

What the evidence actually shows

Real in mice, by surgery, not by a bag of blood

The scientific seed is genuine. In heterochronic parabiosis, surgically joining the circulations of a young and old mouse, Conboy and colleagues (Nature, 2005) restored the regenerative capacity of aged muscle satellite cells and liver. This is reproducible and important. But it is a surgical animal model, not an infusion you can buy. The newer mechanistic twist matters: replacing half of an old mouse's plasma with saline plus 5% albumin (a 'neutral' exchange) matched or beat young-blood exchange for muscle repair, liver fibrosis, and roughly eightfold higher hippocampal neurogenesis (Mehdipour et al., Aging, 2020), with the authors concluding 'young blood is not necessary.' That study is small (n=4 per cohort) with only a preliminary human cell-culture signal.

In humans, a regulator warning and a sponsor-funded near-miss

For people, the controlled evidence is absent. The FDA stated in February 2019 that infusions of plasma from young donors have 'no proven clinical benefit' for aging, memory loss, dementia, Parkinson's, MS, Alzheimer's, heart disease, or PTSD, and flagged infectious, allergic, respiratory, and cardiovascular risks. The most rigorous human plasma-exchange trial, AMBAR (n=347), was in diagnosed Alzheimer's patients, not healthy aging, and did not meet both co-primary endpoints: function improved (ADCS-ADL, p=.03) but cognition showed only a trend (ADAS-Cog, p=.06). It was sponsored by Grifols, the manufacturer of the albumin and immunoglobulin tested, with multiple full-time Grifols employees among the authors.

Evidence quality

Studies, graded, and who paid

Mouse parabiosis rejuvenates some aged tissues A High certainty

Surgically joining young and old mouse circulations restored aged muscle and liver regeneration (Conboy et al., Nature 2005). Real and reproducible, but a surgical animal model.

A single 'young factor' (GDF11) drives rejuvenation C Low certainty

Contested: an independent Novartis group found GDF11 rises with age and inhibits muscle regeneration, and the original antibody also detected myostatin.

Infusing young plasma rejuvenates healthy humans D Very low certainty

No randomized, placebo-controlled evidence. The FDA stated such infusions have no proven clinical benefit and carry real risks.

Plasma exchange (dilution) reverses aging in humans C Low certainty

Biologically plausible and supported in mice by saline-albumin exchange, but unproven in healthy people; the largest human trial was in Alzheimer's, not aging.

Cited studies with type, size, funding/conflicts, and limitations.
#	Study	Type	Size	Funding / COI	Key limitations
1	Conboy et al., Nature 2005 (heterochronic parabiosis)	Experimental animal study	Mice, young 2-3 mo and old 19-26 mo, surgically paired	Independent Academic labs; foundational basic science, no commercial product sponsor.	Surgical mouse model; cannot be ethically or practically reproduced in humans, and is not an infusible product.
2	Mehdipour et al., Aging 2020 (saline-albumin 'dilution' exchange)	Animal study plus ex vivo human serum assay	Mice n=4 per cohort; serum from 4 older humans (65-70)	Independent NIH grants plus Open Philanthropy; authors declare no financial conflicts.	Very small mouse sample; human evidence is only a preliminary cell-culture signal, not clinical outcomes.
3	FDA safety statement, Feb 19 2019 (Gottlieb and Marks)	Regulatory safety statement	N/A	, US federal regulator.	A warning, not a trial; establishes absence of proven benefit and known risks rather than testing efficacy.
5	AMBAR primary results, Boada et al. 2020 (plasma exchange in Alzheimer's)	Randomized, double-blind, sham-controlled trial	347 randomized, mild/moderate Alzheimer's, 41 centers, ~14 months	Industry-funded Sponsored by Grifols, maker of the albumin and IVIG tested; multiple authors are Grifols employees. Sponsor-favorable pattern.	Did not meet both co-primary endpoints; in diagnosed Alzheimer's, not healthy aging, so cannot establish rejuvenation.
6	AMBAR design paper, Boada et al. 2019	Clinical trial design/protocol paper	347 randomized across 4 arms	Industry-funded States verbatim the trial 'is sponsored by Grifols, a manufacturer of therapeutic human serum albumin and intravenous immune globulin.'	Protocol paper only; reports design, not efficacy.

Across the field, the cleanest evidence is animal-only and the strongest human claims cluster around parties who sell the product or the procedure.

Mechanism is genuinely unsettled (young factors versus dilution of old factors versus albumin replacement), so even the optimistic reading does not validate the marketed 'young blood' product.

See who funded the studies behind every Caveat check

Stay neutral

Unproven ≠ disproven

This is largely unproven rather than disproven for the dilution and plasma-exchange angle: it is biologically plausible and shows early mouse signals, but no rigorous trial has tested healthy rejuvenation.

The commercial young-plasma product, by contrast, was sold ahead of any controlled evidence and carries an explicit regulator warning.

The gap

Where claim and evidence diverge

The leap from a surgically joined mouse to a human receiving an infusion is the central gap, and it has never been bridged by a controlled trial.

Even the best human data (AMBAR) tested a disease, not aging, and missed one of its two primary endpoints.

Follow the funding

The money trail

Ambrosia charged about $8,000 per infusion and ran a paid study with no placebo arm, so patients effectively paid to be subjects; it halted treatments within hours of the FDA warning.

The largest human plasma-exchange trial (AMBAR) was sponsored by Grifols, the manufacturer of the very albumin and immunoglobulin products tested, with several authors on its payroll.

Bottom line

The honest read

'Young blood reverses aging' is Unsupported for humans: the mechanism is mouse-only and the commercial product was FDA-warned with no controlled evidence.

The dilution and plasma-exchange research is a legitimate but unproven direction, not a green light to buy infusions.

Falsifiable

What would change this verdict

A randomized, placebo-controlled trial in generally healthy adults showing that young-plasma infusion or plasma exchange slows or reverses validated aging measures (function, biomarkers, or mortality).

Independent replication, funded without a stake in selling plasma, albumin, or the procedure, confirming durable rejuvenation rather than a short-term marker shift.

Receipts

Sources

Common questions